JP2017060462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017060462A5 JP2017060462A5 JP2016155028A JP2016155028A JP2017060462A5 JP 2017060462 A5 JP2017060462 A5 JP 2017060462A5 JP 2016155028 A JP2016155028 A JP 2016155028A JP 2016155028 A JP2016155028 A JP 2016155028A JP 2017060462 A5 JP2017060462 A5 JP 2017060462A5
- Authority
- JP
- Japan
- Prior art keywords
- sirp
- variant
- cancer
- construct according
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150036449 SIRPA gene Proteins 0.000 claims description 214
- 210000004027 cell Anatomy 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 36
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000000903 blocking effect Effects 0.000 claims description 17
- -1 c-Met Proteins 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 235000019419 proteases Nutrition 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102100025221 CD70 antigen Human genes 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims description 4
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 108010091175 Matriptase Proteins 0.000 claims description 4
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 4
- 102000052502 human ELANE Human genes 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000001146 hypoxic effect Effects 0.000 claims description 3
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 2
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 2
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100028801 Calsyntenin-1 Human genes 0.000 claims description 2
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 102100038449 Claudin-6 Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 102100038083 Endosialin Human genes 0.000 claims description 2
- 108010055191 EphA3 Receptor Proteins 0.000 claims description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102000010956 Glypican Human genes 0.000 claims description 2
- 108050001154 Glypican Proteins 0.000 claims description 2
- 108050007237 Glypican-3 Proteins 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims description 2
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims description 2
- 101100069392 Mus musculus Gzma gene Proteins 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 2
- 102100035486 Nectin-4 Human genes 0.000 claims description 2
- 101710043865 Nectin-4 Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 2
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims description 2
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010057249 Phagocytosis Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 208000016450 non-cutaneous melanoma Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 230000008782 phagocytosis Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 102220105280 rs879254406 Human genes 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 229950005972 urelumab Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims 1
- 101000761736 Naja atra Cytotoxin 10 Proteins 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 1
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021101516A JP2021166521A (ja) | 2015-08-07 | 2021-06-18 | Ｓｉｒｐ−アルファ変異体構築物及びその使用 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202775P | 2015-08-07 | 2015-08-07 | |
| US201562202772P | 2015-08-07 | 2015-08-07 | |
| US201562202779P | 2015-08-07 | 2015-08-07 | |
| US62/202,772 | 2015-08-07 | ||
| US62/202,775 | 2015-08-07 | ||
| US62/202,779 | 2015-08-07 | ||
| TW104125902 | 2015-08-10 | ||
| TW104125902A TWI702228B (zh) | 2014-08-08 | 2015-08-10 | 信號調節蛋白α（ｓｉｇｎａｌ-ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ-α）變體構築物及其用途 |
| US14/971,931 | 2015-12-16 | ||
| US14/971,931 US20160319256A9 (en) | 2014-08-08 | 2015-12-16 | Sirp-alpha variant constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021101516A Division JP2021166521A (ja) | 2015-08-07 | 2021-06-18 | Ｓｉｒｐ−アルファ変異体構築物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017060462A JP2017060462A (ja) | 2017-03-30 |
| JP2017060462A5 true JP2017060462A5 (enExample) | 2019-09-12 |
| JP6901834B2 JP6901834B2 (ja) | 2021-07-14 |
Family
ID=57624246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016155028A Active JP6901834B2 (ja) | 2015-08-07 | 2016-08-05 | Ｓｉｒｐ−アルファ変異体構築物及びその使用 |
| JP2021101516A Pending JP2021166521A (ja) | 2015-08-07 | 2021-06-18 | Ｓｉｒｐ−アルファ変異体構築物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021101516A Pending JP2021166521A (ja) | 2015-08-07 | 2021-06-18 | Ｓｉｒｐ−アルファ変異体構築物及びその使用 |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP3913050A1 (enExample) |
| JP (2) | JP6901834B2 (enExample) |
| KR (1) | KR102675219B1 (enExample) |
| AU (2) | AU2016210755B2 (enExample) |
| BR (1) | BR102016018074A2 (enExample) |
| CO (1) | CO2016000671A1 (enExample) |
| CY (1) | CY1124272T1 (enExample) |
| DK (1) | DK3128005T3 (enExample) |
| EA (1) | EA034582B1 (enExample) |
| ES (1) | ES2872528T3 (enExample) |
| HR (1) | HRP20211079T1 (enExample) |
| HU (1) | HUE055605T2 (enExample) |
| IL (2) | IL247114B (enExample) |
| LT (1) | LT3128005T (enExample) |
| MX (2) | MX377080B (enExample) |
| NZ (1) | NZ722947A (enExample) |
| PH (1) | PH12016000277A1 (enExample) |
| PL (1) | PL3128005T3 (enExample) |
| PT (1) | PT3128005T (enExample) |
| RS (1) | RS62150B1 (enExample) |
| SG (2) | SG10201606520SA (enExample) |
| SI (1) | SI3128005T1 (enExample) |
| SM (1) | SMT202100400T1 (enExample) |
| ZA (2) | ZA201605435B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220230T1 (hr) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe |
| KR102233993B1 (ko) * | 2017-07-24 | 2021-03-31 | 한국과학기술원 | 면역 회피성 박테리오파지 |
| US20210040219A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
| SG11202013170RA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| SG11202013167UA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
| MA53493A (fr) * | 2018-08-31 | 2021-07-07 | Alx Oncology Inc | Polypeptides leurres |
| CN109535263B (zh) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRPα突变体及其融合蛋白 |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN115551892A (zh) * | 2020-03-26 | 2022-12-30 | 艾提欧生物疗法有限公司 | 用于耗竭调节性t细胞的双特异性融合蛋白 |
| CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业（上海）股份有限公司 | 一种SIRPα-Fc融合蛋白 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CN116178561B (zh) * | 2021-11-26 | 2025-07-18 | 杭州尚健生物技术有限公司 | 包含SIRPα突变体的融合蛋白 |
| AU2022421675A1 (en) | 2021-12-21 | 2024-05-02 | Fbd Biologics Limited | ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| FI101678B1 (fi) | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JPH11510050A (ja) | 1995-07-25 | 1999-09-07 | イントロヘーネ ベスローテン フェンノートシャップ | 標的遺伝子送達のための方法および手段 |
| CA2246332C (en) | 1996-02-15 | 2009-04-14 | Biosense, Inc. | Catheter based surgery |
| EP0920339A2 (en) | 1996-07-09 | 1999-06-09 | The Johns Hopkins University | Gene delivery system |
| US6613026B1 (en) | 1999-12-08 | 2003-09-02 | Scimed Life Systems, Inc. | Lateral needle-less injection apparatus and method |
| US7662367B2 (en) | 2000-03-02 | 2010-02-16 | Xencor, Inc. | Pharmaceutical compositions for the treatment of TNF-α related disorders |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US7892558B2 (en) | 2004-02-27 | 2011-02-22 | Vaxconsulting | Isolated TNF-alpha peptide and pharmaceutical composition thereof |
| US8518869B2 (en) | 2004-03-29 | 2013-08-27 | Austria Wirtschaftsservice Gesellschaft M.B.H. | Pharmaceutical combined preparation containing a therapeutic protein |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| AU2010215761B2 (en) | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| MX2012000895A (es) * | 2009-07-20 | 2012-06-01 | Univ Nat Cheng Kung | Polipeptidos selectivos para integrina alfavbeta3 conjugada con una variante de albumina de suero humana (hsa) y usos farmaceuticos de los mismos. |
| KR101632312B1 (ko) | 2009-11-03 | 2016-06-21 | 삼성전자주식회사 | 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법 |
| AU2010334974A1 (en) * | 2009-12-22 | 2012-07-12 | Novartis Ag | Tetravalent CD47-antibody constant region fusion protein for use in therapy |
| EP2624868B1 (en) * | 2010-10-08 | 2018-09-26 | City of Hope | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
| US8609621B2 (en) | 2010-11-15 | 2013-12-17 | E I Du Pont De Nemours And Company | Acid-cleavable linkers exhibiting altered rates of acid hydrolysis |
| US9566347B2 (en) * | 2011-02-07 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Peptides and methods using same |
| WO2012172521A1 (en) * | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
| WO2013063076A1 (en) * | 2011-10-25 | 2013-05-02 | Indiana University Research & Technology Corporation | Compositions for and methods of modulating complications, risks and issues with xenotransplantation |
| EP3766511A1 (en) * | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| US9428553B2 (en) * | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| CA2876904C (en) * | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| JP6335189B2 (ja) * | 2012-12-17 | 2018-05-30 | トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療 |
| US9873747B2 (en) * | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| CN106459153B (zh) * | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
| CN113621075B (zh) * | 2014-08-08 | 2024-09-20 | Alx肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
-
2016
- 2016-08-03 BR BR102016018074-0A patent/BR102016018074A2/pt active Search and Examination
- 2016-08-03 EA EA201691384A patent/EA034582B1/ru unknown
- 2016-08-04 IL IL247114A patent/IL247114B/en unknown
- 2016-08-05 JP JP2016155028A patent/JP6901834B2/ja active Active
- 2016-08-05 SG SG10201606520SA patent/SG10201606520SA/en unknown
- 2016-08-05 NZ NZ722947A patent/NZ722947A/en unknown
- 2016-08-05 SG SG10201912880PA patent/SG10201912880PA/en unknown
- 2016-08-05 CO CONC2016/0000671A patent/CO2016000671A1/es unknown
- 2016-08-05 AU AU2016210755A patent/AU2016210755B2/en active Active
- 2016-08-05 ZA ZA2016/05435A patent/ZA201605435B/en unknown
- 2016-08-08 MX MX2016010259A patent/MX377080B/es active IP Right Grant
- 2016-08-08 DK DK16183261.3T patent/DK3128005T3/da active
- 2016-08-08 SM SM20210400T patent/SMT202100400T1/it unknown
- 2016-08-08 PL PL16183261T patent/PL3128005T3/pl unknown
- 2016-08-08 EP EP21161416.9A patent/EP3913050A1/en not_active Withdrawn
- 2016-08-08 EP EP16183261.3A patent/EP3128005B1/en active Active
- 2016-08-08 MX MX2020011759A patent/MX2020011759A/es unknown
- 2016-08-08 LT LTEP16183261.3T patent/LT3128005T/lt unknown
- 2016-08-08 HU HUE16183261A patent/HUE055605T2/hu unknown
- 2016-08-08 SI SI201631255T patent/SI3128005T1/sl unknown
- 2016-08-08 PT PT161832613T patent/PT3128005T/pt unknown
- 2016-08-08 KR KR1020160100696A patent/KR102675219B1/ko active Active
- 2016-08-08 PH PH12016000277A patent/PH12016000277A1/en unknown
- 2016-08-08 ES ES16183261T patent/ES2872528T3/es active Active
- 2016-08-08 RS RS20210831A patent/RS62150B1/sr unknown
-
2019
- 2019-04-29 ZA ZA2019/02673A patent/ZA201902673B/en unknown
-
2021
- 2021-06-14 CY CY20211100522T patent/CY1124272T1/el unknown
- 2021-06-18 JP JP2021101516A patent/JP2021166521A/ja active Pending
- 2021-07-06 HR HRP20211079TT patent/HRP20211079T1/hr unknown
- 2021-08-10 AU AU2021215151A patent/AU2021215151B2/en active Active
- 2021-11-03 IL IL287825A patent/IL287825B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017060462A5 (enExample) | ||
| JP7457764B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| AU2021215151B2 (en) | SIRP-alpha variant constructs and uses thereof | |
| US10047163B2 (en) | Multispecific constructs | |
| EP1605058B1 (en) | Method of screening light chain of antibody light chains | |
| TW201625674A (zh) | 信號調節蛋白α（ｓｉｇｎａｌ－ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ－α）變體構築物及其用途 | |
| CN116888155A (zh) | Ror1特异性变体抗原结合分子 | |
| AU2022206577A9 (en) | Heterotandem bicyclic peptide complexes | |
| Stone et al. | The assembly of single domain antibodies into bispecific decavalent molecules | |
| JP2019525897A (ja) | リジン結合体化免疫グロブリン | |
| CN117043184A (zh) | 抗人血清白蛋白（hsa）的纳米抗体及其应用 | |
| CN113831411A (zh) | 针对l1cam的单域抗体及其衍生蛋白和应用 | |
| Wang et al. | Novel anti-LY6G6D/CD3 T-cell–dependent bispecific antibody for the treatment of colorectal cancer | |
| WO2024193635A1 (en) | Sirp variants and uses thereof | |
| CN116063512B (zh) | 多功能重组抗体及其制备方法和应用 | |
| AU2023332193A1 (en) | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof | |
| AU2023334288A1 (en) | Biepitopic tetravalent antibody targeting egfr | |
| KR20250126789A (ko) | Alpp-특이적 변이 항원 결합 분자 | |
| CA3191859A1 (en) | Nkp30 binders | |
| RU2021112298A (ru) | Полученные путем рационального дизайна новые белковые композиции |